ICS 2013 Scientific Podium Poster Session S32

Speakers
	Friday 30th August 2013
	16:00 - 17:00
	116 Capacity: 350
A Anna Virginia Macaraig Franco ICS Chair K Karl-Dietrich Sievert ICS Chair

16:20

#289 Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on the rat bladder with partial bladder outlet obstruction

Presenter: Seiji Matsumoto

Matsumoto S¹, Watanabe M¹, Hashizume K¹, Wada N¹, Hori J¹, Kita M¹, Iwata T¹, Kakizaki H¹
1. Department of Renal and Urologic Surgery, Asahikawa Medical University
Animal Study, Basic Science, Bladder Outlet Obstruction , Physiology, Voiding Dysfunction

16:25

#290 Inhibitory effects of Tadalafil on prostate cell growth; a study using a novel human benign prostatic hyperplasia xenografts in super-SCID mice

Presenter: Hiroshi Kiuchi

Kiuchi H¹, Tsujimura A¹, Takezawa K¹, Okuda H¹, Fukuhara S¹, Takao T¹, Miyagawa Y¹, Nonomura N¹, Adachi M², Nomura T²
1. Osaka University Graduate School of Medicine, 2. National Institute of Biochemical Innovation
Benign Prostatic Hyperplasia (BPH), Basic Science, Other [PDE-5 inhibitor]

16:30

#291 An inflammatory cytokine IL-1ß is involved in bladder remodelling after partial bladder outlet obstruction in mice

Presenter: Yukiko Kanno

Kanno Y¹, Mitsui T¹, Kitta T¹, Moriya K¹, Tsukiyama T², Hatakeyama S², Nonomura K¹
1. Department of Urology Hokkaido University Graduate School of Medicine, 2. Department of Biochemistry Hokkaido University Graduate School of Medicine
Bladder Outlet Obstruction , Molecular Biology, Physiology, Voiding Dysfunction , Pathophysiology

16:35

#292 Expression of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) receptor and effects of CB1/CB2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats

Presenter: Kang Jun Cho

Cho K J¹, Kim S D², Seo J T³, Kim S H¹, Kim J C¹
1. The Catholic University of Korea, College of Medicine, 2. Jeju National University, School of Medicine, 3. Cheil General Hospital, Kwandong University, College of medicine
Detrusor Overactivity, Pathophysiology, Basic Science

16:40

#293 Dose escalation of a muscarinic antagonist with THVD-201, a novel combination drug product containing tolterodine and pilocarpine (a muscarinic agonist and salivary stimulant)

Presenter: David Staskin

Flugel R¹, Paborji M¹, Duchin K¹, Tremblay T¹, Dmochowski R², Staskin D³
1. TheraVida, 2. Vanderbilt University, 3. Tufts University
Detrusor Overactivity, Overactive Bladder, Pharmacology, Urgency Urinary Incontinence, Urgency/Frequency

16:45

#294 Post hoc responder analyses of subjective and objective outcomes using pooled data from 3 randomised Phase III trials of mirabegron in patients with overactive bladder

Presenter: David Castro Díaz

Castro Díaz D¹, Chapple C², Hakimi Z³, Blauwet M B⁴, Delgado-Herrera L⁴, Fitzsimmons W⁴, Lau W⁴, Mujais S⁴
1. University Hospital Canary Islands, 2. Royal Hallamshire Hospital, Department of Urology, Sheffield, UK, 3. Astellas Pharma Europe Ltd, 4. Astellas Pharma Global Development, Inc
Clinical Trial, Incontinence, Outcomes Research Methods, Overactive Bladder, Quality of Life (QoL)

16:50

#295 Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony)

Presenter: David Staskin

Abrams P¹, Kelleher C², Staskin D³, Kay R⁴, Martina R⁵, Newgreen D⁵, Paireddy A⁵, van Maanen R⁵, Ridder A⁵
1. Bristol Urological Institute, Bristol, UK, 2. Guy's and St Thomas’ NHS Foundation Trust, London, UK, 3. Tufts U School of Medicine, Boston, MA, USA, 4. RK Statistics Ltd, Bakewell, UK, 5. Astellas Pharma BV, Leiden, the Netherlands
Overactive Bladder, Incontinence, Clinical Trial

16:55

#296 A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO). (EudraCT number: 2011-000250-28)

Presenter: Brigitte Bosman

Bosman B¹, Tannenbaum S², Winklewski P¹, Den Adel M¹, Newgreen D¹, Baka-Ostrowska M³
1. Astellas Pharma Europe B.V., 2. Astellas Pharma US B.V., 3. Pomnik-Centrum Zdrowia Dziecka Warsaw
Pediatrics, Clinical Trial, Detrusor Overactivity

Content Visitors (staff only)

Pharmacology

Scientific Podium Poster Session S32

Session Schedule

Comments

Chat